Subcutaneous Immunoglobulins: A Promising Alternative for Immunomodulation?

abstract：:Cancer disease is one of the leading causes of morbidity and mortality worldwide, with approximately 14 million new cases and around 8 million cancer-related deaths yearly. Estimates expect to increase these figures over the next few years. Therefore, it is very important to develop more effective and targeted therapi...

journal_title：Current pharmaceutical design

authors： Caro C,Pozo D

更新日期：2015-01-01 00:00:00

abstract：:The epidermal growth factor receptor (EGFR) has been widely used as a target for novel anticancer agents, such as blocking antibodies and small molecular weight tyrosine kinase compounds. In spite of recent advances in cancer cell biology, leading to the introduction of clinically active new drugs, such as cetuximab, ...

journal_title：Current pharmaceutical design

authors： Bianco R,Damiano V,Gelardi T,Daniele G,Ciardiello F,Tortora G

更新日期：2007-01-01 00:00:00

abstract：:A small but increasing number of gene expression based biomarkers are becoming available for routine clinical use, principally in oncology and transplantation. These underscore the potential of gene expression arrays and RNA sequencing for biomarker development, but this potential has not yet been fully realized and m...

journal_title：Current pharmaceutical design

authors： Flint SM,McKinney EF,Lyons PA,Smith KG

更新日期：2015-01-01 00:00:00

abstract：:Non-enzymatic modification of proteins by reducing sugars, a process that is also known as Maillard reaction, leads to the formation of advanced glycation end products (AGEs) in vivo. There is a growing body of evidence that formation and accumulation of AGEs progress during normal aging, and at an extremely accelerat...

journal_title：Current pharmaceutical design

authors： Unoki H,Yamagishi S

更新日期：2008-01-01 00:00:00

abstract：:Innate and adaptive immunity has been shown to be critically involved in the pathogenesis of atherosclerosis. In particular, immune suppression mediated by regulatory T cells (Tregs) or tolerogenic dendritic cells (DCs) serves as a vital mechanism for regulating pathogenic chronic inflammation in atherogensis, suggest...

journal_title：Current pharmaceutical design

authors： Sasaki N,Yamashita T,Kasahara K,Takeda M,Hirata K

更新日期：2015-01-01 00:00:00

abstract：:The development of targeted therapy drugs acting on tumor growth and progression is greatly expanding these last years. Among them kinase inhibitors have a prominent position and have demonstrated efficacy and clinical benefits in solid and hematologic malignancies. Compared to conventional systemic cytotoxic chemothe...

journal_title：Current pharmaceutical design

authors： Levade M,Severin S,Gratacap MP,Ysebaert L,Payrastre B

更新日期：2016-01-01 00:00:00

abstract：:Obesity was first described as a low-grade inflammatory condition more than a decade ago. However, it is only relatively recently that obese individuals have been described with increased macrophage infiltration of adipose tissue, as well as an increase in the number of "M1" or "classically activated" macrophages. Fur...

journal_title：Current pharmaceutical design

authors： Heilbronn LK,Campbell LV

更新日期：2008-01-01 00:00:00

abstract：:Prostaglandin (PG) D(2), the major cyclooxygenase metabolite generated from immunologically stimulated mast cells, is thought to contribute to the pathogenesis of allergic diseases due to its various inflammatory effects. However, the lack of PGD(2) (DP) receptor antagonists has limited the study of its essential role...

journal_title：Current pharmaceutical design

authors： Mitsumori S

更新日期：2004-01-01 00:00:00

abstract：:In the early 1980s, an "atypical" beta-adrenergic receptor was discovered and subsequently called the beta (3)-adrenoceptor (beta(3)-AR). Agonists of the beta(3)-AR were observed to simultaneously increase lipolysis, fat oxidation, energy expenditure and insulin action leading to the belief that this receptor might se...

journal_title：Current pharmaceutical design

authors： de Souza CJ,Burkey BF

更新日期：2001-09-01 00:00:00

abstract：:Catheter ablation for rhythm control in atrial fibrillation has been recognized as an established treatment. Patients with atrial fibrillation suffer from an increased risk of thromboembolic events. Long-term stroke risk and mortality have been shown to be reduced after catheter ablation, still the procedure per se is...

journal_title：Current pharmaceutical design

authors： Vrachatis DA,Giannopoulos G,Kossyvakis C,Panagopoulou V,Vavuranakis M,Papaioannou TG,Pagoni S,Pyrgakis VN,Cleman MW,Deftereos SG

更新日期：2017-01-01 00:00:00

abstract：: ...

journal_title：Current pharmaceutical design

authors： Li K,Wang X

更新日期：2018-01-01 00:00:00

abstract：:The final aim/target of Pharmaceutical Sciences is to design successful dosage forms for effective therapy, considering individual patient needs and compliance. Development of new drug entities, particularly using peptides and proteins, is growing in importance and attracting increased interest, as they are specifical...

journal_title：Current pharmaceutical design

authors： Degim IT,Celebi N

更新日期：2007-01-01 00:00:00

abstract：:Elevated levels of Low Density Lipoprotein cholesterol (LDL-C) are directly associated with increased risk for atherosclerotic cardiovascular and cerebrovascular events. Statins have been used to control serum LDLC and this has translated into reduction in cardiovascular and cerebrovascular events. However, despite hi...

journal_title：Current pharmaceutical design

authors： Ali A,Costanzo P,Hoye A

更新日期：2018-01-01 00:00:00

abstract：BACKGROUND:Preterm birth is the major cause of perinatal mortality and morbidity worldwide. Attempts to reduce the burden may be proactive using biochemical or biophysical prediction and preventative measures. If these efforts fail, then the approach may have to be reactive using tocolytics to inhibit spontaneous prete...

journal_title：Current pharmaceutical design

authors： Lamont RF,Jørgensen JS

更新日期：2019-01-01 00:00:00

abstract：:Doxorubicin has been a constituent of antitumor drug protocols for a broad spectrum of cancers for more than two decades. Side effects and resistance continue to be important limitations. Drug targets responsible for both side effects and anti-tumor activity are cell membrane receptors, cell membrane lipids, nucleic a...

journal_title：Current pharmaceutical design

authors： Taatjes DJ,Fenick DJ,Gaudiano G,Koch TH

更新日期：1998-06-01 00:00:00

abstract：:The introduction of highly active anti-retroviral therapy (HAART) for Human Immunodeficiency Virus (HIV) infection has significantly improved the life expectancy of HIV positive patients. Hepatitis C virus (HCV) co-infection is common in HIV infected patients and is now a significant cause of morbidity and mortality. ...

journal_title：Current pharmaceutical design

authors： Fabris P,Barnes E,Tositti G,Giordani MT,Grasso A,De Lalla F

更新日期：2004-01-01 00:00:00

abstract：:Cardiovascular disease (CVD) is one of the major lifestyle associated disorders and leading causes of death worldwide. The incidence of CVD in diabetic patients has increased up to 3 folds and it became the major risk for diabetes associated morbidity and mortality. Insulin resistance and oxidative stress both play a ...

journal_title：Current pharmaceutical design

authors： Bagul PK,Banerjee SK

更新日期：2013-01-01 00:00:00

abstract：BACKGROUND:Although medications should only be prescribed in pregnancy if benefits to the mother outweigh the risk to the fetus, drug use in pregnancy especially prescribed and over-the-counter analgesics, is very common. OBJECTIVE:The objective of this review is to present an update on known changes in analgesic disp...

journal_title：Current pharmaceutical design

authors： Price HR,Collier AC

更新日期：2017-01-01 00:00:00

abstract：:Evasion of apoptosis, the cell's intrinsic death program, is a hallmark of human cancers including neuroblastoma. Also, failure to undergo apoptosis may cause treatment resistance, since the cytotoxic activity of anticancer therapies commonly used in the clinic, e.g. chemotherapy, gamma-irradiation or immunotherapy, i...

journal_title：Current pharmaceutical design

authors： Fulda S

更新日期：2009-01-01 00:00:00

abstract：BACKGROUND:Reversible cholinesterase inhibitors, when given prophylactically before exposure to organophosphates, are able to decrease organophosphate-induced mortality. However, the efficacy of pyridostigmine, the only pre-treatment substance approved by the US Federal Drug Administration, is unsatisfactory. METHODS:...

journal_title：Current pharmaceutical design

authors： Lorke DE,Nurulain SM,Hasan MY,Kuca K,Petroianu GA

更新日期：2017-01-01 00:00:00

abstract：:Tumor metastasis is an important prognostic factor regarding long-term survival rate of cancer patients. At present, no imaging modality or technique is ideal for diagnosis of metastases. Molecular imaging has provided a fantastic tool for tumor metastases imaging. Based on the current medical imaging tools such as ma...

journal_title：Current pharmaceutical design

authors： Qiao R,Zhu R,Gao M

更新日期：2015-01-01 00:00:00

abstract：:The pharmacophore concept is central to the rational drug design and discovery process. Traditionally, a pharmacophore is defined as a specific three-dimensional (3D) arrangement of chemical functional groups found in active molecules, which are characteristic of a certain pharmacological class of compounds. Herein, b...

journal_title：Current pharmaceutical design

authors： Tropsha A,Zheng W

更新日期：2001-05-01 00:00:00

abstract：:DAP12 is a novel immunoreceptor tyrosine-based activation motifs (ITAM)-bearing transmembrane adapter molecule. This molecule, together with its partner receptor complex molecules including the killer cell activating receptors (KARs), myeloid DAP12 associating lectin-1 (MDL-1), triggering receptor expressed on myeloid...

journal_title：Current pharmaceutical design

authors： Aoki N,Kimura S,Xing Z

更新日期：2003-01-01 00:00:00

abstract：:Mesenchymal Stem Cells (MSCs) are a population of adherent cells that can differentiate into mesenchymal lineage populations (cartilage, bone and fat tissue). In addition, they seem to be able to differentiate also into a broader type of lineages other than the original mesodermal germ layer. Bone marrow MSCs are a st...

journal_title：Current pharmaceutical design

authors： Mariani E,Facchini A

更新日期：2012-01-01 00:00:00

abstract：:The targeting of drugs to skeletal muscle is an emerging area of research. Driven by the need for new therapies to treat a range of muscle-associated diseases, these strategies aim to provide improved drug exposure at the site of action in skeletal muscle with reduced concentration in other tissues where unwanted side...

journal_title：Current pharmaceutical design

authors： Ebner DC,Bialek P,El-Kattan AF,Ambler CM,Tu M

更新日期：2015-01-01 00:00:00

abstract：:Synaptic plasticity is now known to occur at glutamate synapses throughout the brain, including the neocortex, and to play a role in neurodevelopment as well as in a broad spectrum of adult neural functions. Here the hypothesis that synaptic plasticity, specifically long term depression, is the neural substrate that m...

journal_title：Current pharmaceutical design

authors： Selemon LD

更新日期：2014-01-01 00:00:00

abstract：:The plants of the Colchicum family were known during the archaic period in Greece for their deleterious properties. Later on, they were used for the treatment of podagra. The treatment was introduced by the ancient Greek physicians and passed on to the Byzantine and Arabian physicians to endure until nowadays. The fir...

journal_title：Current pharmaceutical design

authors： Tsoucalas G,Papaioannou T,Panayiotakopoulos G,Saridaki Z,Vrachatis DA,Karamanou M

更新日期：2018-01-01 00:00:00

abstract：BACKGROUND:Vaginal infections caused by non-albicans species have become common in women of all age groups. The resistance of species such as Candida parapsilosis to the various antifungal agents is a risk factor attributed to these types of infections, which instigates the search for new sources of active compounds in...

journal_title：Current pharmaceutical design

authors： C de Lima L,A S Ramos M,Toledo LG,Rodero CF,Hilário F,Dos Santos LC,Chorilli M,Bauab TM

更新日期：2020-01-01 00:00:00

abstract：BACKGROUND:The global burden of gastrointestinal cancers, including colorectal, stomach, and esophageal cancers is rising steadily. Several therapeutic approaches have been considered for the treatment of GI carcinomas. However, none showed to halt or cure the disease. There is a need to develop effective targeted mole...

journal_title：Current pharmaceutical design

authors： Mahmood MQ,Shukla SD,Dua K,Shastri MD

更新日期：2017-01-01 00:00:00

abstract：:The prevalence of type 2 diabetes is rising at an alarming rate worldwide. Coronary artery disease (CAD) is the leading cause of morbidity and mortality in the diabetic population. Future CAD risk should be routinely assessed in patients with diabetes as specific subgroups might benefit from information derived from c...

journal_title：Current pharmaceutical design

authors： Karastergiou K,Kaski JC

更新日期：2008-01-01 00:00:00